Use of α1β1 integrin receptor inhibitor and IGF-β1 inhibitor in the treatment of kidney disease

摘要

The present invention provides methods for treating (i.e., delaying the onset of, slowing the progression of, and/or reversing) kidney disorders (e.g., renal glomerulonephritis and/or renal fibrosis). Certain of these methods involve administering an .alpha.1.beta.1 integrin receptor inhibitor optionally in combination with a TGF-.beta.1 inhibitor. The present invention also provides a mouse model for kidney disease wherein the mouse does not express a normal collagen type 4 composition in the GBM (i.e., it does not incorporate collagen .alpha.3(IV), .alpha.(IV), and .alpha.5(IV) chains into its glomerular basement membrane) and does not express the .alpha.1.beta.1 integrin receptor.